Short-term human prostate primary xenografts:: An in vivo model of human prostate cancer vasculature and angiogenesis

被引:42
作者
Gray, DR
Huss, WJ
Yau, JM
Durham, LE
Werdin, ES
Funkhouser, WK
Smith, GJ
机构
[1] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
关键词
D O I
10.1158/0008-5472.CAN-03-2700
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Transgenic spontaneously occurring and transplantable xenograft models of adenocarcinoma of the prostate (CaP) are established tools for the study of CaP progression and metastasis. However, no animal model of CaP has been characterized that recapitulates the response of the human prostate vascular compartment to the evolving tumor microenvironment during CaP progression. We report that primary xenografts of human CaP and of noninvolved areas of the human prostate peripheral zone transplanted to athymic nude mice provide a unique model of human angiogenesis occurring in an intact human prostate tissue microenvironment. Angiogenesis in human kidney primary xenografts established from human renal cell carcinoma and noninvolved kidney tissue, a highly vascular organ and cancer, was compared with angiogenesis in xenografts from the relatively less vascularized prostate. Immunohistochemical identification of the human versus mouse host origin of the endothelial cells and of human endothelial cell proliferation in the human prostate and human kidney xenografts demonstrated that: (a) the majority of the vessels in primary xenografts of benign and malignant tissue of both organs were lined with human endothelial cells through the 30-day study period; (b) the mean vessel density was increased in both the CaP and benign prostate xenografts relative to the initial tissue, whereas there was no significant difference in mean vessel density in the renal cell carcinoma and benign kidney xenografts compared with the initial tissue; and (c) the number of vessels with proliferating endothelial cells in primary xenografts of CaP and benign prostate increased compared with their respective initial tissue specimens, whereas the number of vessels with proliferating endothelial cells decreased in the benign kidney xenografts. Short-term primary human prostate xenografts, therefore, represent a valuable in vivo model for the study of human angiogenesis within a human tissue microenvironment and for comparison of angiogenesis in CaP versus benign prostate.
引用
收藏
页码:1712 / 1721
页数:10
相关论文
共 71 条
  • [1] Targeting the prostate for destruction through a vascular address
    Arap, W
    Haedicke, W
    Bernasconi, M
    Kain, R
    Rajotte, D
    Krajewski, S
    Ellerby, HM
    Bredesen, DE
    Pasqualini, R
    Ruoslahti, E
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (03) : 1527 - 1531
  • [2] Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
    Benjamin, LE
    Golijanin, D
    Itin, A
    Pode, D
    Keshet, E
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) : 159 - 165
  • [3] The controls of microvascular survival
    Benjamin, LE
    [J]. CANCER AND METASTASIS REVIEWS, 2000, 19 (1-2) : 75 - 81
  • [4] Benjamin LE, 1998, DEVELOPMENT, V125, P1591
  • [5] Borre M, 2000, CLIN CANCER RES, V6, P1882
  • [6] Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting
    Borre, M
    Offersen, BV
    Nerstrom, B
    Overgaard, J
    [J]. BRITISH JOURNAL OF CANCER, 1998, 78 (07) : 940 - 944
  • [7] Bostwick D G, 1998, Semin Urol Oncol, V16, P118
  • [8] Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies
    Bostwick, DG
    Wheeler, TM
    Blute, M
    Barrett, DM
    MacLennan, GT
    Sebo, TJ
    Scardino, PT
    Humphrey, PA
    Hudson, MA
    Fradet, Y
    Miller, GJ
    Crawford, ED
    Blumenstein, BA
    Mahran, HE
    Miles, BJ
    [J]. UROLOGY, 1996, 48 (01) : 47 - 57
  • [9] BRAWER MK, 1994, CANCER, V73, P678, DOI 10.1002/1097-0142(19940201)73:3<678::AID-CNCR2820730329>3.0.CO
  • [10] 2-6